Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Covington
Argus Health
Medtronic
Healthtrust
Deloitte
Boehringer Ingelheim
Mallinckrodt
Cerilliant

Generated: August 18, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 9,101,660 protect, and when does it expire?


Patent ► Subscribe protects ACTOPLUS MET and is included in one NDA. There has been one Paragraph IV challenge on Actoplus Met.

This patent has thirty-one patent family members in twenty-five countries.

Summary for Patent: ► Subscribe

Title:Solid preparation
Abstract: The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which is useful as a therapeutic drug for diabetes and the like, and which is superior in preparation characteristics such as content uniformity and dissolution property of the insulin sensitizer and the active ingredient (except insulin sensitizers), preparation hardness and the like.
Inventor(s): Koike; Masahiko (Osaka, JP), Koyama; Hiroyoshi (Osaka, JP), Hamaguchi; Naoru (Osaka, JP)
Assignee: Takeda Pharmaceutical Company (Osaka, JP)
Application Number:10/530,262
Patent Claim Types:
see list of patent claims
Compound; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
ACTOPLUS MET
metformin hydrochloride; pioglitazone hydrochloride
TABLET;ORAL021842-001Aug 29, 2005ABRXYesNo► Subscribe► SubscribeY
Takeda Pharms Usa
ACTOPLUS MET
metformin hydrochloride; pioglitazone hydrochloride
TABLET;ORAL021842-002Aug 29, 2005ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-294045Oct 7, 2002
PCT Information
PCT FiledOctober 06, 2003PCT Application Number:PCT/JP03/12781
PCT Publication Date:April 15, 2004PCT Publication Number: WO2004/030700

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2005113999► Subscribe
Portugal1561472► Subscribe
Poland219608► Subscribe
Poland376176► Subscribe
New Zealand552559► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Cipla
Harvard Business School
AstraZeneca
Cantor Fitzgerald
Dow
Merck
Johnson and Johnson
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot